Associations between lifetime classic psychedelic use and cardiometabolic diseases
Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychede...
Guardado en:
Autores principales: | , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da2659 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:1bec952e2b6e4e63b6ebf6dd00da2659 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:1bec952e2b6e4e63b6ebf6dd00da26592021-12-02T15:33:13ZAssociations between lifetime classic psychedelic use and cardiometabolic diseases10.1038/s41598-021-93787-42045-2322https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da26592021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93787-4https://doaj.org/toc/2045-2322Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.Otto SimonssonWalter OsikaRobin Carhart-HarrisPeter S. HendricksNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-5 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Medicine R Science Q |
spellingShingle |
Medicine R Science Q Otto Simonsson Walter Osika Robin Carhart-Harris Peter S. Hendricks Associations between lifetime classic psychedelic use and cardiometabolic diseases |
description |
Abstract The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases. |
format |
article |
author |
Otto Simonsson Walter Osika Robin Carhart-Harris Peter S. Hendricks |
author_facet |
Otto Simonsson Walter Osika Robin Carhart-Harris Peter S. Hendricks |
author_sort |
Otto Simonsson |
title |
Associations between lifetime classic psychedelic use and cardiometabolic diseases |
title_short |
Associations between lifetime classic psychedelic use and cardiometabolic diseases |
title_full |
Associations between lifetime classic psychedelic use and cardiometabolic diseases |
title_fullStr |
Associations between lifetime classic psychedelic use and cardiometabolic diseases |
title_full_unstemmed |
Associations between lifetime classic psychedelic use and cardiometabolic diseases |
title_sort |
associations between lifetime classic psychedelic use and cardiometabolic diseases |
publisher |
Nature Portfolio |
publishDate |
2021 |
url |
https://doaj.org/article/1bec952e2b6e4e63b6ebf6dd00da2659 |
work_keys_str_mv |
AT ottosimonsson associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases AT walterosika associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases AT robincarhartharris associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases AT petershendricks associationsbetweenlifetimeclassicpsychedelicuseandcardiometabolicdiseases |
_version_ |
1718387068170665984 |